Sollers College

Tag: careers in pharma

  • In the realm of pharmacovigilance, is the cloud solution the latest development?

    In the realm of pharmacovigilance, is the cloud solution the latest development?

    • New technology and systems support every aspect of the drug development process, which is changing exponentially.
    •  Before biological products are submitted for market clearance, pharmacovigilance (PV) is one of the most important steps in the medication development cycle. It makes sure that the products fit the intended safety profile. 
    • One of the innovative and promising developments aimed at enhancing the PV process as a whole is cloud-based solutions.
    • Before being approved for commercial use, all biopharmaceuticals go through extensive clinical trial testing to ensure their safety and effectiveness. The three components of PV are systems, operations, and surveillance. It is a comprehensive process.
    • To ensure that safety is upheld, PV requires significant data entry and analysis. It also looks for adverse events (AEs) that have not been discovered yet or for variations in the severity of AEs that have.
    • The industry is working to address several major issues that persist despite the process’s significant advancements. 
    • These issues include more consistency in reporting adverse events, difficulties with spontaneous reporting, the preference for efficacy over safety, constraints on presented reports, analysis of digital medical records, and combining systems.

    The industry’s present obstacles
    One problem that arises in clinical practice is the inconsistent reporting of adverse events. Because adverse effects can happen even days after taking a medication, people may not always recognize them at the time and may not appropriately report them to a healthcare provider. 

    This is critical information for the pharmaceutical company since it may point to a possible problem with the drug’s safety, particularly if a certain adverse event is reported frequently.

    The number of adverse event cases is increasing in tandem with the complexity of the disease, creating a challenge in the development of a therapeutic that is both efficacious and has a suitable safety profile.

    The industry is currently facing a special problem with system integration, as many organizations find it difficult to incorporate new technologies like cloud computing into their established systems. To guarantee high-quality signal analysis, it is essential to standardize medical domains, signal definitions, adverse events, and medical coding. Regrettably, system integration is still difficult because there isn’t a common framework.

    Systems designed to identify adverse events (AEs) are receiving real-time data from telehealth devices such as social media and activity bracelets. As more and more organizations use telehealth in their research, new information sources are being introduced. To develop the advanced analytical tools needed to assess the data’s worth, new PV protocols will be needed.

    There will continue to be a need for more PV capabilities in the future as the global rules continue to get more complicated. In nations with developing regulatory environments, policies will be codified and adapted accordingly. This is according to an industry report.

    The field of pharmacovigilance is changing due to rapidly advancing technology and shifts in the delivery of healthcare worldwide. As a result, many organizations are having to incur substantial costs for system upgrades and maintenance.

    The industry has since changed as a result, and many biopharma companies are now thinking about how new technologies and advanced analytics could enhance their current PV systems.

    PV technology of the future

    Many pharmaceutical companies are now placing a high premium on developing next-generation PV systems to lower costs while simultaneously enhancing patient safety, which is of utmost importance.
    It has been observed that a new system ought to have the following four essential elements:

    • Intellectual case processing to help increase the effectiveness and caliber of the AE life cycle by automating data input and processing.

    • Operational and aggregate reporting that is scalable, easy to use, and built to handle big data sets and high-volume usage.

    • Signal detection, assessment, and management that combine and simplify systems and procedures to enable analysts to carry out validation and assessment tasks without ever leaving the system, resulting in more accurate and efficient data management.

    • Safety measures that find benefits that can enhance patient outcomes while detecting, evaluating, and assisting in the prevention of safety-related problems. These metrics make use of newly developed real-world sources, safety data that already exists, and supervised and unsupervised machine learning.

    Solutions leveraging the cloud
    Cloud-based solutions represent a novel approach to pharmacovigilance assistance.

    Pharmacovigilance has several benefits, one of which is the ease of upgrading systems. Every time new developments in technology or modifications are made to drug safety regulations, systems that evaluate data on drug adverse events (AEs) are automatically updated to comply with the new requirements.

    Upgrades to on-premises safety software are regarded as very expensive and oftentimes time-consuming, which can create company disruption. Pharma organizations can greatly benefit from this.

    One other benefit of using cloud-based technologies in PV is that it makes data integration easier. Traditional PV systems require manual data transmission to an external solution.

    As technology has advanced over the past few years, cloud-based PV solutions have become more and more popular. It has been observed that incorporating cloud technology can facilitate healthcare professionals’ access to medication safety information, regardless of whether the data was reported during clinical studies, in addition to the pharmaceutical business.

  • What advantages do non-clinical careers offer dentists?

    What advantages do non-clinical careers offer dentists?

    • Many medical professionals find clinical work enjoyable. However, some dentists opt for non-clinical careers to put their medical degrees to use in different ways.
    • There are numerous career options available to medical doctors, in addition to the fact that they treat patients. Non-clinical dental careers are becoming more popular.
    •  An occupation classified as non-clinical is one that does not involve treating or testing patients.
    •  However, these positions still call for the knowledge, training, and experience of medical doctors.
    •  In addition, non-clinical careers act as a transitional step between the dental industry and a corporate career.
    •   For some people who have a connection to the science of medicine, clinical care can be difficult.
    •   After many years of effective practice, seasoned practitioners are eager for a change of scenery and fresh challenges.
    •  However, using qualifications that dentists already have and continuing education after BDS.

    Listed below are a few benefits of applying your medical training to a career outside of medicine:

    1.   Because treating patients can be taxing, some medical professionals are looking for positions that don’t involve the pressures of making evaluations and carrying out life-saving procedures.
    2.   A practicing physician might put in lengthy hours and spend a significant amount of time away from the office while on call for hospital emergencies.
    3.   There are non-clinical careers that offer a better work-life balance.
    4.   Non-clinical careers have good opportunities in the corporate world as well.
    5.   It is impossible to make as much money in a clinical setting as possible by leveraging your pharmaceutical experience.
    6.   Non-clinical careers offer a lot of opportunities. Discovering relevant non-clinical careers in healthcare such as pharmacovigilance, clinical trials, medical transcription, clinical research, medical coding, and medical claim officer.

    Find your area of expertise in healthcare.

    Individuals from different cultural backgrounds shift to non-clinical work by enrolling in certificate programs for a variety of reasons. Still, others might be seeking a change of scenery, while others might find that non-clinical work is a more adaptable option.  Many individuals want to investigate their switching careers. Whatever your reason, working in a variety of non-clinical healthcare positions will allow you to develop the knowledge and abilities you need to pursue a career in healthcare. 

     

  • What advantages does data science bring to the medical sector?

    What advantages does data science bring to the medical sector?

    •  Data Science is one of these technologies that allows us to deal with such a large amount of data with more sophistication. Patients’ health is tracked by utilizing stored data.
    • It is now possible to identify disease symptoms early thanks to data science in the healthcare sector. 
    • Doctors can now monitor their patients’ conditions remotely thanks to a number of cutting-edge tools and technologies.
    • With data science and machine learning applications, wearable technology can inform doctors about their patients’ health conditions. As a result, junior physicians, medical assistants, or nurses from the hospital may visit these patients’ homes.
    • To diagnose these patients, hospitals can also use various tools and devices. These devices, which are based on data science principles, gather information from patients, including their heart rate, blood pressure, body temperature, etc. 
    • Doctors can access their patient’s health information in real time by using mobile applications that provide updates and notifications. 
    • A competent medical professional or nurse can then diagnose the patient and offer specific treatments that can be administered at home by junior medical professionals or nurses.
    • The application of data science to the care of patients is one example of how using technology can make this possible.

    Data Science’s Benefits for Healthcare

    Data science makes healthcare systems and procedures possible. Healthcare systems have improved workflow, and it helps increase productivity in diagnosis and treatment. These are the main objectives of the healthcare system:

    • The healthcare system’s operational efficiency
    • Lowering the possibility of unsuccessful treatment
    • To promptly provide the necessary care.
    •  To prevent needless emergencies because of a doctor’s lack of availability
    • Patients’ wait times should be cut down.

     

    How to begin a career as a Healthcare Data Scientist?

    Data scientists in the healthcare industry need education, skills, and experience. Here are some ideas for how to investigate a career in this field:

    Establish a strong mathematical and statistical foundation: If you want to establish a strong mathematical and statistical foundation, starting with a thorough understanding of these topics is a great place to start. These topics serve as the fundamental building blocks of data science. The main topics to study are calculus, linear algebra, probability, and statistical inference.

    Earn a bachelor’s degree: To develop a solid academic foundation and gain essential foundational knowledge, think about enrolling in a bachelor’s program in a field that is closely related to data science. Computer science, statistics, math, and healthcare are all relevant fields. 

    Become a programming expert: To expand your skill set, concentrate on becoming an expert in programming languages used frequently in data science, such as Python or R. Numerous tasks involving data, such as data manipulation, analysis, and modeling, make extensive use of these languages. 

    Learn about healthcare-specific libraries and frameworks like TensorFlow or PyTorch as well, as they were created specifically to meet the needs of data scientists working in the healthcare industry.

    Understand the specialized knowledge in healthcare: Acquire knowledge of the terms, rules, and information sources used in the healthcare sector. Acquire knowledge of clinical trials, medical coding, electronic health records (EHRs), and healthcare analytics.

    Consider pursuing a master’s degree or a Ph.D. in a related field, such as data science, health informatics, or biomedical informatics. Advanced degrees offer specialized knowledge and opportunities for research in healthcare data science.

    Gain useful skills through projects: Engage in real-world projects that require healthcare data analysis. This could entail conducting research, collaborating with healthcare organizations, or using publicly available healthcare datasets.

     By engaging in such practical activities, you can build a portfolio that illustrates your competence but also highlights your capacity to manage healthcare data effectively.

    The key to being an efficient healthcare data scientist is constant learning and improvement. Continually update your knowledge and abilities by attending conferences, joining professional organizations, keeping up with market trends, and pursuing online courses and certifications. You can increase your chances of succeeding in this exciting and rewarding field by adhering to these guidelines. In addition, you can reaffirm your commitment to lifelong learning.

    Data Scientists’ Place in the Healthcare Industry

    Data scientists put all data science methods into practice to integrate medical software. To develop predictive models, the data scientist draws insightful conclusions from the data. Data scientists have general responsibilities in the medical field:

    • Gathering data from medical facilities and pharmaceutical companies
    • The evaluation of hospitals’ equipment management needs
    • Data organization and sorting for use
    • Using a range of tools, performing data analytics
    • Using algorithms applied to the data to gain insights.
    • Developing forecasting tools with the development team

    Health-related predictive analytics

    Information is one of the key components of healthcare analytics in the modern era. Incomplete information could make a patient’s situation worse. To acquire patient information or data, something must be done. 

     Information about the patient is acquired, assessed, and then examined once more to seek trends and connections. This process seeks to pinpoint a disease’s phases, level of harm, signs, and symptoms, and other characteristics.

    A predictive analytics algorithm built on data science then predicts the patient’s status. It also encourages the development of treatment strategies. Predictive analytics is therefore a very useful technique and important for the healthcare sector.

    Future Healthcare Outcomes via data science

    • There is a bright future for healthcare data science, a future that will be revolutionizing. 
    • Technologies and methods from data science can transform healthcare, enhance patient outcomes, and spur new treatments. 
    • Data science supports personalized medicine, predictive analytics, early disease detection, precision diagnostics, and treatment optimization. 
    • Healthcare data is increasingly available from wearables, genomics, eHealth, and MRIs. 
    • Artificial intelligence and machine learning algorithms can help with clinical decision-making, drug discovery, and medical research. 
    • Healthcare industry operations, resource allocation, and population health management can also benefit from data-driven strategies. 
    • Healthcare data science integration has the potential to improve productivity, effectiveness, and patient-centered care, resulting in significant advancements in the industry.
  • Does big data analytics work for pharmacovigilance?

    Does big data analytics work for pharmacovigilance?

    The use of big data analysis facilitates safety evaluations, comparative effectiveness studies, and investigational trials.


    Big data analytics in PV has numerous uses:

    • Pre-marketing drug safety surveillance: Big data analytics techniques have also proven useful in research. Data mining automates standardization, statistical scoring, and signal prioritization, reducing labor costs and improving biology understanding.
      Big data analytics is used by the pharmaceutical industry for post-marketing safety surveillance to identify drug safety signals earlier, assess risk, and interpret clinical trial findings.

    Drug safety signals are identified earlier, risks are evaluated, and clinical trial findings are interpreted using big data analytics by the pharmaceutical industry. This is for post-marketing safety surveillance. The pharmaceutical industry benefits from big data analytics in terms of time and cost savings. In addition, it benefits from logistical assistance in detecting signals in large data sets.

    • Regulatory decision-making: Regulatory agencies rely on big data analytics for the detection of signals in ADR cases as well as vaccine monitoring. Regulatory agencies decide how to implement signals, such as label changes and benefit-risk monitoring of medications, once they identify them using big data analysis.

    Clinical application: In clinical application, this analysis offers data on the illness, prior consultations, diagnostics, test outcomes, and therapies. Everything is centralized and easily searchable, including blood type, allergies, diseases, potential medications, and vital sign measurements. Big data analytics is being used in everyday practice to quickly provide accurate information in an emergency.

    • Clinical trials: The following examples show how advanced analytics can add value to clinical trials.
    • Increased data quality by automating the analysis of various types of data
    • Effective data mining that increases the transparency of data exploration by detecting deviations and differences.

    NEW APPLICATIONS OF BIG DATA ANALYTICS IN PV

    • COVID-19 medications and vaccines
      In the COVID-19 pandemic, PV analysis using big data is essential for reducing false information and giving patients the right information and explanations about drug use. This analysis produces useful data about a disease, such as hidden patterns, unknown trends, correlations, and patient preferences.
      The following are some significant PV analytics applications in COVID-19:
      Benefit-risk analysis; improved drug and vaccine safety; quicker compliance; better patient protection
      Using big-scale data analysis using data mining tools helps identify novel and unidentified AEFI and AESI in subpopulations that are understudied or left out of trials. This allows for continuous monitoring of safety concerns regarding these vaccines after introduction.

    “BIG DATA ANALYTICS IN PV: DATA SECURITY”
    Data privacy is crucial whenever information is posted online and made readily accessible for research. Users maintain the confidentiality of patient identity-related information. Using social media to assess advancing medical knowledge still raises ethical questions. The most crucial one is the guarantee that patient identity remains private. Technology has not advanced the current set of rules and regulations protecting privacy rights. Procedures were created to ensure that only data that had been through a data minimization step should be accessible to registered end users for analysis. However, the raw data were kept accessible in very specific circumstances to allow contacting the patient if necessary.

    A PV Perspective on big data analytics

    PV-related fields have some limitations despite big data’s impact.

    Big data analytics is also difficult due to issues such as incorrect, missing, or duplicate data, bias, confounding variables, and validation procedures. With low-quality data algorithms, decision-makers may have difficulty making assumptions about specific signal detection.
    When patients seek care at different institutions or practices, their care may be recorded in multiple electronic health records. There may not be a significant enhancement to administrative data by structured data due to unstructured data.

    An Outlook on big data analytics in PV

    Big data can find connections between patient data in various datasets. The development of standards for signal detection, the use of an integrative approach to signal detection, the improvement of data mining software and tools, the application of data mining to other product safety and regulatory issues, and other future directions will help to overcome the current limitations of big data analytics in PV.

    Summary
    For drug safety, large data analytics has succeeded in locating new ADEs and ADRs connected to drugs. Big data can contribute more to PV efforts, despite the many obstacles to be overcome. The use of extensive data in PV will probably continue to advance as updated methods, tools, and data sources for drug safety surveillance are developed. Last but not least, the true test of big data’s worth will be how well it helps identify drug safety problems.

  • Pharmacovigilance in Preventive and Therapeutic Medicine

    Pharmacovigilance in Preventive and Therapeutic Medicine

    The importance of systematic pharmacovigilance is being gradually acknowledged by all companies. Additionally, the importance of patient-centricity is increasing, and there are more publicly available safety data as a result.

    Therefore, all businesses are increasingly aware of proactive pharmacovigilance, regardless of their size and product line-up.

    Regulations for risk management and product safety have undergone a period of significant change, with regulations in developed regions becoming stricter and those in emerging markets evolving quickly.

    The importance of emerging markets has caused a shift in the market’s geographical focus. Pharmacovigilance operations have become more complex because of alliances created between various international stakeholders, including generic producers, distributors, service providers, and technology providers.

    Additional elements that add to this complexity are the change in the ratio of small and large molecules, the shift in the therapeutic area’s focus, and the rigor required to gather safety data for new classes of products.

    Determining that all safety systems and PV practices used by an organization firmly tie into a single, truly global PV framework is crucial. This is because proactive PV depends on compliance with various regulations and guidelines. Establishing such a framework takes much more than just collecting safety information from distributors, partners, and affiliates.

    To establish a global PV strategy, a global PV system was established.

    Global Pharmacovigilance Network

    A PV system’s structure, procedures, and intended results define it. It is described as a system used by a company to carry out its legal obligations and tasks related to PV. It was created to track the security of approved pharmaceutical products and identify any changes to their risk-benefit ratio. All licensed products must be protected from adverse drug reactions (ADRs) by a strong, global system, no matter where they are licensed or where they are sold.

    There must be a strong, global system in place to record and manage adverse drug reactions for all licensed products. This is true wherever similar products are sold in the world, and wherever they are licensed in the markets. A global system must also be able to execute all downstream tasks, including regular reporting and safety surveillance.

    A company’s corporate quality system must include a global PV system as a fundamental component. It is complicated by nature and necessitates the seamless cooperation of several parties such as company divisions, such as regulatory and medical affairs, as well as commercial, corporate, customer service, and complaint intake departments, as well as the entire company’s leadership.

    Therefore, the system must consider the accountability and responsibilities of each of these entities in terms of how they directly or indirectly relate to safety. Additionally, harmonization and standardization of process workflows are essential to consider their interdependencies.

    The following crucial components are necessary for a successful global PV system, and MAHs may use specialty safety consulting and service providers who can suggest and implement them:

     

    https://sollers.college/life-science/drug-safety-and-pharmacovigilanc/

     

    There are various ways to explain the detailed PV Quality System with documented procedures.

    1. A sufficient number of knowledgeable and skilled employees is required in all areas of operations.
    2. Effective business collaborations with partners, associates, and suppliers. A few of these include contracts with suppliers and business partners, as well as the sharing of safety information.

    The PV system’s final and most important component, corporate level structure, does two things:

     1) aligns the various entities that are within its scope;

     2) makes it possible for compliance from all business units (BUs) and therapeutic areas (TAs); and 

    3) strengthens the connection between the main PV function and specific affiliates.

    The system requires responsiveness to emerging trends, including new operating structures, emerging public data sources, and providers. Effective oversight of safety-related activities across all entities in scope is also crucial.

    Developing and Planning a Global PV System Strategy

    • There are numerous challenges for organizations of all sizes when it comes to establishing a global PV system, regardless of the type of organization.
    • The risk of non-compliance and the lack of internal availability of safety expertise may be a significant challenge for a small business with a finite number of products.
    • The number of distributors and business partners, as well as the manufacturer’s focus and diligence on product safety, may present the biggest difficulties.
    • The most significant challenges for large businesses with a diverse product mix and extensive global reach may be ensuring consistent worldwide SOPs for safety and risk management across product categories and regions, as well as efficient oversight of all parties.
    • The foundation for establishing an efficient system is a carefully thought-out strategy that considers both the organization’s short- and long-term business plans.
    • There must be a thorough examination of the present situation and an analysis of the gaps in terms of people, procedures, and technology.
    • A thorough understanding of the various regulatory requirements, as well as the global organizational structure and operating model necessary to enable the crucial level of oversight and control, is required. An ideal framework for setting up a successful global PV system will be created.
    • A comprehensive understanding of safety laws and international business practices will be utilized to develop a strategic plan.

    Synopsis

    Globalization of the economy and the impact of cutting-edge technologies on healthcare delivery will present significant challenges and opportunities for life sciences decision-makers. Medical knowledge, techniques for its analysis, and emerging sources of knowledge are transforming the current reactive system into a proactive one.

     Globally, regulations are also changing to take a more proactive stance, but they still tend to be too procedure-focused, which frequently stifles innovation. Furthermore, the technical resources necessary for a successful benefit-risk analysis are still in the early stages of development.

     All safety systems and PV practices must be tightly integrated into a truly global PV framework for organizations to succeed in the current environment.

    An approach that considers all relevant factors is required to set up such a framework. This system considers the responsibility and commitments of all entities, and how they relate to safety.

    Our mission at Sollers College is to provide students with the fundamental information and practical skills to meet the demands of the rapidly expanding healthcare, life science, and pharmacovigilance fields. 

    Graduates from Sollers will advance into rewarding careers with leading international corporations. 

    To learn how we can assist you in formulating your future, call or drop by today.

     

  • Pharmacovigilance: A promising approach for better health outcomes

    Pharmacovigilance: A promising approach for better health outcomes

    Pharmacovigilance: A promising approach for better health outcomes 

    The pharmaceutical industry and drug regulators face numerous challenges in pharmacovigilance, patient safety, and addressing areas of unmet medical needs in an environment where development costs have increased exponentially while filings and launches have decreased significantly.

    The confluence of these problems not only intensifies access limitations and costs over time but also generates a pressing need for investments in new, improved PV capabilities. To provide analyses to regulators, healthcare professionals, and patients quickly and transparently, these improved capabilities will enable businesses to improve the processing of safety data.

    To improve the accessibility, assessment, and dissemination of the information, it is necessary to review the current PV systems. This fact is causing businesses to work with local, national, and regulatory agencies and healthcare delivery systems to develop a model that will guarantee operational efficiencies and satisfy the needs of doctors, patients, and payers by automating a significant portion of the event reporting and processing.

    The status of PV must change to one that benefits the market, regulators, and patients to constitute a true breakthrough. We present a few crucial factors to think about for a thorough PV transformation to realize this paradigm.

    Effective collaborations

    Up until a circumstance that brings to light drug safety concerns, the tendency has been to keep things as they are. Because of these obligations, the pharmaceutical industry has long regarded PV as a sacred domain whose only goal is the observance of predetermined data collection and reporting requirements. Proper techniques for dealing with new issues and challenges called for solutions that were more involved, complicated, and resource intensive.

    An organizational transformation for PV has also been accelerated by changes in the regulatory environment in the US. The traditional method of signal detection and evaluation through existing PV strategies has become an unworkable paradigm due to the need for new adverse event reporting, safety monitoring requirements, and risk management. As a result, the creation of a flexible and effective next-generation PV solution will necessitate not only internal transformational leaps but also creative external partnerships.

    The proactive risk-benefit assessment and timely transactional PV components, such as the receipt and processing of adverse events and the cost-effective creation of aggregate reports, should all be capabilities of the new PV model that is more effective and agile. The extent to which these changes occur will depend on several variables, including advanced technologies, effective means of exchanging safety information, and inspirational leadership that inspires fresh partnerships between various partners and disciplines. These innovative methods will make it easier to move from a discipline that has historically been reactive to a proactive paradigm of viable and effective models intended to continuously improve patient safety.

    For risk identification, risk assessment, and risk management, this proactive system depends on external, creative partners. A major focus of improving drug safety systems is ongoing risk-benefit analysis throughout the product life cycle. This is especially true after launch when the ongoing evaluation of risk-benefit is necessary as new data become available. As a result, PV departments will need to actively advance their science by combining existing PV methods with those from epidemiology, health services research, and health economics. By combining various data, scientific disciplines, and methodological expertise, this discipline integration will give PV departments a synergistic advantage in detection and management.

    Only through collaboration between businesses, policymakers, academic institutions, and healthcare delivery systems will it be possible to supplement current PV methods with new disciplines.

    Increasing patient safety with pharmacovigilance 

    The pharmaceutical industry and drug regulators face numerous challenges in pharmacovigilance, patient safety, and addressing areas of unmet medical need. There has been a significant decline in filings and launches during this time of exponentially increasing development costs.

    Increasing access limitations and costs over time are generated by these problems, as well as a pressing need to invest in better PV technologies. To provide analyses to regulators, healthcare professionals, and patients quickly and transparently, these improved capabilities will enable businesses to improve the processing of safety data.

    Reviewing PV systems is necessary to improve the accessibility, assessment, and dissemination of information. This requires businesses to work with local, national, and regulatory agencies and healthcare delivery systems. They will develop a model that will guarantee operational efficiencies and satisfy the needs of doctors, patients, and payers. In addition, they will automate a significant amount of event reporting and processing.

    The status of PV must change to one that benefits the market, regulators, and patients to constitute a true breakthrough. 

    Effective collaboration

    Up until a circumstance that brings to light drug safety concerns, the tendency has been to keep things as they are. Because of these obligations, the pharmaceutical industry has long regarded PV as a sacred domain whose only goal is the observance of predetermined data collection and reporting requirements. Techniques are applied to address concerns and challenges that require solutions that are more involved, complicated, and resource intensive.

    Organizational transformation for PV has also been accelerated by changes in the regulatory environment in the US. The traditional method of signal detection and evaluation through existing PV strategies has become an unworkable paradigm. This is due to the need to enhance adverse event reporting, safety monitoring requirements, and risk management. As a result, the creation of a flexible and effective next-generation PV solution will necessitate not only internal transformational leaps but also creative external partnerships.

    The revised PV model should provide proactive risk-benefit assessment and timely transactional PV components, such as the receipt and processing of adverse events and the cost-effective creation of aggregate reports, which are all capabilities that are more reliable and agile. The extent to which these changes occur will depend on several variables. These variables include advanced technologies, reliable means of exchanging safety information, and inspirational leadership that inspires successful partnerships between various partners and disciplines. These innovative methods will make it easier to move from a discipline that has historically been reactive. This is because they are viable and effective models intended to continuously improve patient safety.

    For risk identification, risk assessment, and risk management, this proactive system depends on external, creative partners. A major focus of improving drug safety systems is ongoing risk-benefit analysis throughout the product life cycle. This is especially true after launch when the ongoing evaluation of risk-benefit is necessary as updated data become available. As a result, PV departments will need to actively advance their science by combining existing PV methods with those from epidemiology, health services research, and health economics. By combining various data, scientific disciplines, and methodological expertise, this discipline integration will give PV departments a synergistic advantage in detection and management.

    Only through collaboration between businesses, policymakers, academic institutions, and healthcare delivery systems will it be possible to supplement current PV methods with novel disciplines.

    Globalization of markets

    Cost savings have helped multinational corporations transition from using global sourcing as a trend to largely common practice. Global sourcing, though, offers more benefits than just cost savings. For PV, global sourcing will entail integrating on-site and offshore capabilities as well as creating centres of excellence abroad for the creation and application of surveillance techniques. Global outsourcing will therefore be successful if these capabilities are integrated and methods with a direct impact on risk management and risk communication are improved, in addition to reducing PV costs.

    Proactive safety initiatives are planned.


    Launching a product is an important step in the development of a drug because it signifies the conclusion of discussions between the pharmaceutical industry, regulatory agencies, and patients. As part of the new PV vision, stakeholders should be educated even before the commercial launch. Therefore, it would be possible to implement earlier close monitoring and education practices before the drug was released on the market with the help of conditional marketing authorizations. The patient safety advertisements will also improve and increase adverse event reporting. Furthermore, it would lead to the best possible use of the product and an improvement of the benefit-risk profile of the drug.

    This would give PV the chance to raise awareness about safety concerns while also taking advantage of the chance to collect more thorough safety data during the early stages of the drug’s use. This strategy would produce a reasonable hybrid alternative by combining common safety surveillance techniques with the evaluation of post-marketing safety using sizable mortality and morbidity trials before the drug’s approval and introduction.

    Reliability
    Safety findings must be conveyed in a timely, clear, and concise manner for the new paradigm of an improved and proactive pharmacovigilance system to be successful. To guarantee that all available safety data are used in the risk assessment of potential signals, this will necessitate the development of a unified adverse event reporting system, including a storage database and analytical tool that would be shared by sponsors. Such a cross-company safety data tool could be made possible by recent technological developments, enabling more accurate background rate determination and signal detection.

    A “Next generation PV” model’s development will be heavily influenced by current shifts in the cost and insurance coverage of new medications, the regulatory landscape, and the effects of global financial changes on the pharmaceutical industry. Pharmaceutical companies are being pushed harder than ever to reinvent themselves by speeding up development, being agile and efficient, addressing unmet medical needs that are already present, and enhancing patient value. To transform current systems into high-performing organizations with new signal detection technologies, emerging markets, world-class talent on safety assessment, and cost-efficiencies consistently integrated, PV departments will need to form cooperative partnerships with existing and new stakeholders. However, in order to implement these organizational changes, the company will need to change its corporate philosophy.

    A career in drug safety and pharmacovigilance can be started by enrolling in Sollers College today. 

    Every step of the curriculum will help you with your PV skills. There are training programs available from Sollers college for students who are prepared to build their profiles. 

    You can increase your skill set with the help of Sollers college, who also offer lots of opportunities to do so. Achieve success in your career with in-demand certifications. 

    A variety of career options are consistently created by Sollers College’s distinctive curriculum, which also provides the best professional supervision and rapid learning support.

    Sollers College built a path to the significant pharmaceutical industry so that you could learn and share your knowledge. Don’t limit your options to the pharmaceutical market!!!

     

  • The Revolutionary Impact of AI on Drug Safety and Pharmacovigilance

    The Revolutionary Impact of AI on Drug Safety and Pharmacovigilance

    • Drug safety, or pharmacovigilance, is an essential step in the drug development process for ensuring the health and safety of healthcare consumers.
    • It also informs drug manufacturers of any adverse reactions (ADRs) that their products may cause in a particular patient. It is also referred to as PV or drug safety.
    • The PV process begins early in the development of a drug with phased clinical trials to gather information about its efficacy and safety.
    • PV entails “identifying, tracking, evaluating and preventing negative outcomes” from drug therapies. Over the last few years, it has experienced “huge growth”:
    • This is due to the enormous number of drugs currently being developed, as well as the requirement that each manufacturer submit evidence of a drug’s efficacy and safety to the Food and Drug Administration (FDA) of the United States and other comparable organizations around the world.

    PV, which continues throughout the drug’s lifecycle, typically consists of two main pillars:

    Processing of a single case: The manual collection, examination, and reporting of ADRs are all included in the processing of a single case for Individual Case Safety Reports. The case processing process typically consumes and occupies a lot of resources.

    This resource might be better used for more critical tasks instead of case processing. PV data volumes are increasing dramatically, which has led to an increase in case processing costs.

    Detecting signals or conducting post-marketing surveillance (PMS): They continuously keep an eye on ADRs. In addition to using clinical data from sources like electronic health records, data from medical devices, customer surveys, and social media, signal detection also uses clinical data from sources like medical assessments of adverse drug reactions, medical literature, databases, and clinical trials.

    • PMS is crucial in identifying rare benefits or issues with a drug that would otherwise remain unnoticed for years because it involves long-term monitoring.
    • There are a few differences between pre-marketing trials and post-marketing trials. Typically, pre-marketing trials last only a few months, while post-marketing studies involve a much larger population, including smaller subgroups that are not represented in limited clinical studies.
    •  PMS can also last for an indefinite period of time, whereas clinical trials typically last for a few weeks or months.

    PMS can manifest in three different ways:

    1. spontaneously reporting cases to the FDA; c
    2. conducting post-marketing studies like clinical studies; and
    3. engaging in active surveillance.

    Increased costs for traditional PV (and the business case for AI)

     ADRs are on the rise due to several factors, including aging populations, increased public awareness, and pharmaceutical products. It’s easy to understand how the costs of PV have risen sharply for pharmaceutical companies when this is combined with the increased regulatory requirements over the past few years. The cost of PV is steadily rising in terms of expenditures and resources.

    Developments of AI in PV

    • All these factors have led to a shift in many PV and PMS strategies’ emphases from primarily reactive to proactive risk management using AI tools. This is because these tools are capable of locating, gathering, and analyzing vast amounts of data quickly.
    • Free-form text data is common in the healthcare industry, so trained natural language processing (NLP) and machine learning (ML) algorithms can recognize, extract, and classify ADR data from this type of unstructured data.
    • Automation of manual, repetitive, and standard tasks with case processing is possibly the most significant potential application of AI in PV, particularly the PMS component of PV. Each case will be processed, which will also free up valuable resources to work on tasks that are more difficult and add value.
    • AI-powered big data analytics can also assist in the discovery of drug-event associations for populations, enhancing the identification of potential occurrences and enhancing risk-benefit analyses.
    • NLP algorithms can analyze large datasets from medical literature, medical records, and other text data in real-time. In this method, signals pointing to unanticipated advantages or negative effects are watched for by trained analysts and AI.
    •  The signals offer real-world intelligence compared to data mining from controlled clinical settings, such as how reports can be generated using natural language generation (NLG) technology, allowing experts to add additional analysis and polish.
    •   The auto-coding of terms used by consumers and non-medical staff to official medical ontologies is another application of AI in PV. Another use case is the automatic text conversion of ADRs.

    The Drug Safety and Pharmacovigilance Training Programs at Sollers College provide a curriculum that is in line with current industry demands, is extremely competent, and prepares professionals in the pharmaceutical industry for a career in this constantly expanding and highly regulated sector.

    Sollers College has provided a proven approach to student success and sustained growth by combining in-depth knowledge of PV programs with unmatched skill development and services for student recruitment and retention. Through this strategy, student success and sustainability are enhanced.

     

  • Aggregate Reporting: Consequences, Criteria, and Constraints

    Aggregate Reporting: Consequences, Criteria, and Constraints

    Aggregate reporting is the process of compiling and submitting aggregate reports to regulatory agencies throughout the product’s life cycle (during the pre-marketing and post-marketing phases) to provide a thorough understanding of the safety profile of the medication.

    A drug’s safety profile and risk-benefit analysis are highlighted in aggregate reports, which are the database’s cumulative reports. 

    Why should aggregate reporting be done?

    The purpose of aggregate reports is to provide an assessment of the benefit-risk analysis balance that pharmaceutical companies should submit to regulatory authorities during the post-authorization phase.

     But why is reporting in aggregate so important?

    • Real-world drug safety data must be gathered in the post-marketing phase because more people are exposed to the drugs in the real world than in clinical trials. 
    • Rare AEs (adverse events) that have not yet been recognized may become apparent at this stage. 
    • Patients with underlying diseases who receive medications in real life frequently experience a variety of side effects. Such information will be essential for further research to determine the product’s limitations when provided through aggregate reports.
    • Additionally, the post-marketing studies carried out to show drug efficacy and risk stratification can reveal deviations in the Benefit-Risk balance of pharmaceuticals. But drawing that conclusion without further research and continuing or stopping the medication is illogical. 
    • The product’s benefit-risk profile must therefore be continuously monitored. It is imperative to identify and report new and evolving information on risks and evidence of benefits, all of which are amply reflected in aggregate reports.
    • The pre-marketing and post-marketing phases of a product both call for aggregate reports.
    •  In both the pre-marketing and post-marketing phases of a product, these aggregate reports are necessary. These reports each pinpoint and emphasize a distinct risk or benefit. 

    The following list includes the overall reports for each stage. Aggregate reports are categorized as follows.

    Aggregate Reporting: Consequences, Criteria, and Constraints

    Aggregate Reporting Constraints

    • Compiling aggregate reports and submitting them legally can be challenging due to the nature of the process.
    • Due to the wide variety of reports that must be included in the submission, the documentation process is frequently quite difficult. Even though switching to electronic platforms has made sorting reports easier, it is still difficult.
    • In a broader sense, scheduling and assigning tasks among the workforce by choosing the appropriate resource for each process continues to be a problem that needs to be solved. 
    • Aggregate reporting is still a labor-intensive manual process even after the proper resources have been allocated and tracking it with spreadsheets might make it even more disorganized.
    • There must be consistency in any report updates. The regulatory team, the safety and clinical team, and the marketing team, among others, must provide timely updates on information from various stakeholders. Each report must be tracked from submission to approval by pharmaceutical companies. They must also recognize and check the line listings for accuracy, considering the variety of data involved.
    • The reporting process involves enormous amounts of data, and those amounts keep growing every day. The risks of errors leading to non-compliance findings are a major source of worry for the pharmaceutical industry.
    • In addition to all these difficulties, regional regulatory requirements are a common worry. The regulatory guidelines are periodically revised in stages and are not consistent worldwide, necessitating the use of multiple trackers for various products and nations.
    • Companies are still realizing that some of these issues can be resolved through the harmonization of regulations, on which the international regulatory bodies are still working. They enable improved coordination and quick data access. It reduces the time needed to file the data for submission while improving search criteria and sorting capabilities.
    • Pharmaceutical companies will discover that automating regulatory reporting lifecycle management will improve quality in authoring, and will ensure that reviews are completed in time, providing respite to stakeholders. The complexity of aggregate reporting is on the rise. 

    Important Product Features

    • Schedule Management for Reports
    • Predefined templates for PADER, PSUR, PBRER, DSUR, CTPR, and other documents
    • Electronic Authoring
    • Collaboratively examine activities based on workflow.
    • Regulatory Surveillance
    • Version Control Access Control
    • Rule Auto Update
    • Sharing Combined Reports
    • Notifications and alerts
    • Analytics and Insights

     Sollers provides certificates for graduates in the Advanced Drug Safety and Pharmacovigilance Program. This unique program was developed for professionals who want to work in the field of drug safety and is based on the popular, business-based Oracle Argus Safety Database Software. Pharmacovigilance is currently the focus of the healthcare industry to balance risks and benefits.

     The Advanced Drug Safety and Pharmacovigilance Programs at Sollers College offer a curriculum that is in line with the needs of the market, is very competent, and prepares professionals for a career in the pharmaceutical sector. These programs were created to satisfy the requirements of this heavily regulated and ever-expanding industry.

  • Pharmacovigilance’s liability in healthcare analytics

    Pharmacovigilance’s liability in healthcare analytics

    Most pharmacovigilance and ADR reporting initiatives are aimed at educating practitioners. In the future, healthcare providers will be required to possess pharmacovigilance competencies in order to rationally prescribe, distribute, and monitor medications.

    It is imperative to anticipate, diagnose, manage, and report adverse drug reactions as part of rational and safe prescribing. There is a significant shortage of pharmacovigilance skills among healthcare professionals, according to various studies.

    Pharmacovigilance is also demonstrated by practicing pharmacists, dentists, and nurses at low levels of knowledge, skills, and behaviors, consistent with a lack of undergraduate training in this field.

    There are many factors contributing to the current inadequate response to many ADRs, including unawareness of pharmacovigilance, low skills in reporting ADRs, ignorance, and fear of legal liability.

    In order to increase the proficiency of healthcare professionals, several interventions have been used (such as protocols, educational workshops, or email), but these interventions are costly or do not achieve clinically significant effects.

    Pharmacovigilance in the pharmaceutical industry

    Pharmacovigilance within the industry aims to protect patients from needless harm by identifying previously unrecognized drug hazards, elucidating predisposing factors, disputing false safety signals, and quantifying risk to benefit. These objectives are essentially the same as those of regulatory agencies. Regulatory bodies and businesses are now working more closely together and sharing information, despite the possibility that they may have different perspectives.

    Pharmacovigilance Monitoring on a Global Scale

    Pharmacovigilance now has a solid scientific foundation and is essential to efficient clinical practice.

    To meet the needs of contemporary public health and the expectations of the public, the discipline must advance. A complex and crucial relationship is involved in drug safety monitoring.

    An Overview of the Importance of Medical Reporting

    Data concerning adverse drug reactions during the pre marketing phase is inadequate due to the small number of patients used in clinical trials and their inability to represent the general population. Information about uncommon but serious adverse reactions, chronic toxicity, and use in specific groups or drug interactions is frequently lacking. 

    Additionally, the conditions for using medicines differ from those in clinical practice, and the period is limited.

    The ability to detect less frequent but occasionally very serious ADRs depends on post-marketing surveillance. ADRs that are less frequent but occasionally very serious must be able to be detected. ADRs should be reported by medical professionals everywhere because they can help save other people’s lives as well as their patients.

    To find the side effects associated with drugs, signal detection is important. To be sure, the caliber of reports as well as the number of reports sent to national pharmacovigilance centers are equally significant. 

    When reports are completed by medical professionals with knowledge of pharmacology, such as pharmacists, doctors, nurses, physician assistants, dentists, etc., the quality of the reports is unquestionably higher. Even better would be for pharmacy information systems to be able to record and retrieve it.

    Sources of data for pharmacovigilance

    Information is gathered by pharmacovigilance from a variety of sources:

    • Medical studies and observational data published in global medical literature, 
    • Natural reporting of adverse reactions by healthcare professionals (link to adverse reactions), 
    • Pharmaceutical companies are among the sources.
    • Statistics about healthcare as well as details on drug consumption.

    Inference

    Adverse drug reactions are identified, reported, monitored, and prevented by healthcare professionals. This is due to their expertise in drugs and their role as mentors for safe and effective drug use. Prescribers who have made the transition from being focused on products to being patient-focused are still not afraid of making the change.

    Programs for ongoing professional development and a stronger knowledge base at the undergraduate level can both help close the gap. Community pharmacists’ empowerment and involvement in patient record checks and electronic reporting could also lower ADR-related incidents.

     The effectiveness of national pharmacovigilance systems is unlikely to increase without effective identification and fulfillment of the training needs of pharmacists and other healthcare professionals, which may hinder patient safety.

    Sollers uses dynamic course material developed by industry academics who are knowledgeable about the field. 

     Having a small class size ensures individualized attention for every student while giving them access to the latest technologies.

     By taking advantage of our PV professional learning programs, you can not only become a qualified candidate right away, but you can also guarantee your value to any company when you step into the working world in the future.

  • Is pharmacovigilance different now that COVID-19 has been eradicated?

    Is pharmacovigilance different now that COVID-19 has been eradicated?

    When COVID-19 shocked the world in 2020, the importance of drug safety jobs increased. As countries looked for the best way to combat the pandemic, pharmacovigilance also became a hot topic. 

    To determine the best outcomes for COVID patients while attempting to stop the virus in its tracks, the pressure was put on the life sciences market and the industry. Drug interactions and their effects are evaluated, monitored, and discovered in the healthcare system.

    COVID-19 has been devastatingly impacting global health, but the pandemic and its demands have forced the pharmaceutical and pharmaceutical care industries to innovate and develop new methods that can collect and use more reliable and effective data about the safety of drugs.

    The urgent task of gathering and analyzing data from pandemic clinical trials as well as post-marketing settings was suddenly given to pharmacovigilance teams all over the world. Pharmaceutical companies conducted research and innovation at this time to monitor vaccine efficacy and safety. 

    A growing pharmaceutical industry and increased global drug demand are driving up demand for pharmacovigilance experts.

    Many of these innovative techniques improved pharmacovigilance and are now employed to keep track of both newly released medicines and those that have been on the market for some time. Better patient outcomes were the outcome.

    But what exactly are these changes?

    A better way to respond to change before the pandemic, the pharmacovigilance sector was resistant to change. However, the industry had to quickly adapt and think differently due to the urgent need for swift action.

     

    The COVID-19 crisis forced teams in the life sciences to re-evaluate their methods and showed them that change can be a good thing.

    The use of automation and AI tools are being expanded.


    To meet the needs of the healthcare market while ensuring worker safety, many life sciences industries have evaluated and implemented cutting-edge technologies and tools.

    The standards of drug safety procedures have continued to rise, thanks in large part to AI, which at this point became a crutch. The use of AI-enabled chatbots is now being extended to automate more administrative tasks and collect data where human error is unlikely to occur.

    By automating time-consuming intake tasks, this tool allows healthcare professionals to concentrate on the tasks that are most relevant to patients.

    Aside from AI, PV has been altered by:

    • increased drug testing
    • accelerated drug development
    • Effective management and quality control
    • accurate market analysis and forecasting
    • Estimating product costs

    Future developments are anticipated to meet the demand for personalized medicines and therapies as AI’s application to drug safety continues to grow.

    An updated era for tracking adverse reactions


    Before the pandemic, adverse event reporting systems (AERS) were in use. These systems, which are a component of AI technology, became even more important in the effective monitoring of drug safety and public health when the pandemic occurred. To stop misinformation from leading to unnecessary hype and dangerous trends, diligent reporting was required.

    The health industry is now more transparent because of this new era of adverse event reporting, giving patients clearer information about medications and treatments as well as their effects.

     Sollers college is driven to produce results and is enthusiastic about the development of the health and life sciences industry. 

    Our top priority is to find the best candidates for the best PV roles so that the industry can advance. Students can continuously enhance this process to the values and tenacity of Sollers College.

    For career advancement, look through our extensive list of pharmacovigilance positions. Do you wish to learn more? If you need assistance, please get in touch with us.

  • A six-level framework for streamlining pharmacovigilance

    A six-level framework for streamlining pharmacovigilance

    To gather information about adverse events and address patient safety, pharmacovigilance is essential. The AE case processing segment, a crucial component of PV, currently faces many difficulties.

    Adverse event reporting is costly, time-consuming, and subject to human error, which could hurt patient safety. The industry will significantly benefit in the future from the promise of intelligent automation made possible by artificial intelligence and machine learning.

    Artificial intelligence (AI) and machine learning (ML) have the potential to revolutionize the sector through automation technologies.

    Level 0: The level of automation is not present

    Stage zero, or manual case processing, excludes any automation support. The entire case intake and processing process are fully manual, and the case submission process and any decision-making that results from it are entirely handled by human users. Intervention systems may improve this performance, but the execution of the process remains schematic.

    In terms of balancing compliance and cost, this may be all that is ever required for organizations with low volumes of adverse events. Several digital tools exist to automate steps in the process, which provide progression to the next stage.

    Level 1: This level of service is only for assistance

    Initially, autonomy can only help; human supervision is essential.

    For many years, PV has included this level of automation to varying degrees. Auto-narratives and letter generation are two examples of how proven tools transform structured case data by manually selecting from pre-defined templates that are set up to match company-specific nuances. Instead of investing time and resources in manually creating these free text summaries, these examples show how auto-narratives and letter creation work.

    Currently, most PV departments are automated with only minimal assistance.

    Level 2: Automate a portion of the process

    As automation advances, fewer scenarios call for manual intervention, though human users still monitor case processing and still intervene when necessary. In our analogy of an autonomous vehicle, automation enables the system to take over multiple tasks at once, such as steering, acceleration, and deceleration.

    For instance, automating data extraction and identification from source documents speeds up case processing; doing this work in advance improves the ability to identify follow-ups and reduces the need for multiple copies.

    Level 3: Automated systems that are conditional

    Another situation where AI can do work-intensive tasks is bulk literature screening. Smart algorithms can parse more content in less time with better accuracy than PV professionals could by reading peer-reviewed literature and reports for AE signals over hundreds of hours.

    Although there will be false positives requiring review, it is interesting to note that an automated PV system using natural language processing is more likely to find arbitrary mentions of ailments or products than a human reader. Alternatively, this can be done algorithmically, as it is when associated with null flavor values. 

    In either case, functionality reducing the need for human resource usage lowers the costs of pharmacovigilance, improves safety outcomes, and frees up PV professionals for more value-driven activities.

    Level 4: This is the level that represents a high degree of automation

    Due to its high level of automation, the system can handle each aspect of numerous case types. System quality and compliance are not always ensured by manual action, even when notified by human users.


    At this point, the system can carry out all the operations necessary to receive and register a case report. This includes validation, duplication checks, and data entry from compatible systems. Medical evaluations are possible for a wide range of case types, and ML is increasingly enabling QC.

    Following learned criteria, the triage function assigns cases a ranking for reporting purposes; a request for intervention is only made when a case deviates from the data’s assumptions. Depending on the health authority in question, the client risk profiles, and how well the case complies with other requirements, manual intervention may or may not be necessary when submitting to authorities or partner organizations. Depending on several factors, case closure and archiving can be automated.

    Level 5: level of complete automation of the process

    A PV system can execute autonomous case processes and submissions for all case types once it reaches full safety automation status. For any given case or report recipient, no manual intervention is necessary.

    When the process is fully automated, AI can act to reduce patient risk if the system sends an intervention request, but no human responds appropriately. The actions are pre-set and automated for safety reasons, whether that means launching a national alert about a drug-related adverse event or putting a hold on dispensing a batch.

    Positive effect on the economy

    The life sciences industry gains from autonomous case processing in several ways. The traditional case processing workflow can be turned on its head, and labor-intensive and expensive processes can be automated, saving organizations time and money.

    As a first step, companies need to assess their current situation and set precise goals in terms of PV automation. Risk tolerance should be considered when setting these goals. Even though there is no one-size-fits-all strategy, everyone should start small and introduce automation gradually as technology develops to the point where it can solve unimaginable problems.

                                                                                 Sollers partners with industry-leading employers in all fields.

    Sollers prepares a comprehensive plan from start to finish based on a detailed analysis of your needs. Students will gain both the background and skills they need to succeed at an affordable price.

                                                                                Get your career off to a successful start.

  • Reformatting PV Methods for the Digital Era

    Reformatting PV Methods for the Digital Era

    It is challenging to imagine that pharmacovigilance will stay on the periphery of the digital transformation that has occurred, given the increased emphasis on expedited drug approvals and the enormous amount of data generated every day.

    Pharmaceutical PV companies must adapt to a “digitalized future” where technology is a crucial component of PV procedures. To reduce complexity, this includes automating and streamlining the information streams, from reporting to case processing. Once automated, companies must start to consider using artificial intelligence to enhance the value of their data.

    Organizations can transform the challenge of managing an abundance of data into an opportunity by utilizing artificial intelligence (AI) and data science approaches. Not only can tedious and repetitive tasks be eliminated by a well-designed, automated, AI-powered PV system, but it can also reduce human errors and effectively analyze huge amounts of data.

     With the help of insights gained from combining various big data sources, this can even give teams the ability to detect predictive signals. In the end, this might help experts form more knowledgeable conclusions and give better advice about the safety of their products.

    The Components of Digital PV

    Pharmaceutical organizations must understand that technology is not a panacea, though. Starting with a framework of both digital and operations transformation, success in digital PV should be possible. Teams will need to develop additional advantages to get the most value out of a digital approach to PV.

    1. The appropriate people in the right positions: The next-generation PV team needs new talents. Today’s standard PV department has a gap between each employee’s technological and medical expertise. Companies will need to make investments in upskilling and creating cross-functional teams at both the management and operational levels to create the PV workforce of the future.

    B.Increasing patient empowerment: High-quality PV processes, as well as high-quality health care, have both come to be known for their patient-centricity. Connecting with patients at every stage of the product’s development, from testing to marketing, is the mark of a truly patient-centric organization. Patient involvement early in the design process can help teams pinpoint improvement opportunities. Digital products that are effective in practical use scenarios will be created with this technology.

    C.Adopting an innovative culture: To integrate and utilize technology to its fullest extent, it is essential to foster the right culture that encourages innovation and data-centric thinking. This will make predictive safety possible, offer insightful data to the entire business, and boost productivity. A cutting-edge, digitized PV department is capable of leading change throughout the company.

    As the sector continues to transition to a digital future, putting the foregoing into practice will be crucial to building the framework for a next-generation PV department.

    Pharmacovigilance strategies are influenced by the following key innovations:

    • Cloud, 
    • big data, and 
    • natural language processing

    Big Data
    Big Data in healthcare refers to the enormous and continuously expanding volumes of computerized medical data that are accessible in the form of electronic health records, administrative or health claims data, disease, and drug monitoring registries, and more. 

    Various types of medical data have accumulated without being recognized for their value or potential applications. With the development of new, powerful computer tools that can process and analyze large amounts of data, “big data” has grown in importance and can now be used for prediction purposes.

    When it comes to pharmacovigilance, big data includes resources like these:

    • Signal detection.
    •  Validation of safety signals for drugs and vaccines. 
    • online channels; and 
    • social media

    PV’s Outlook
    The need for digital transformation, which is necessary to avoid being disrupted and to maintain competitiveness, is still being driven by the shift to a digital-first economy. It is important that pharmaceutical companies begin their digital transformation right away by creating plans and setting up the necessary infrastructure. To support further technology adoption and business growth, a methodical approach incorporating cloud adoption and digitalization is the key.

    A phased approach to incorporating technologies like AI into the pharmacovigilance process can pay significant dividends as capabilities develop. The best results can be achieved when organizations and safety teams are accustomed to automating and modifying autonomous workflows.

    Sollers college common goal is to inspire students to be successful in the beginning, growing, and maintaining careers in the life sciences. Our approach is comprehensive and integrated in all respects.

     Sollers college tried-and-true model, which combines upfront knowledge of life science programs with unparalleled skill development and services for student recruitment and retention, produces sustainable growth and facilitates rapid student success.

  • Drug Safety Outsourcing: Enhancing Customer Experience

    Drug Safety Outsourcing: Enhancing Customer Experience

    The increased prices of drug research and development as well as post-market surveillance must be counterbalanced in part by wiser, sleeker, greater agility that saves money without compromising quality.

    Outsourcing can be an important part of the solution if companies work hard to find the right partner, choose the best contracting agreement, and pursue a solid relationship model.

    Primary outsourcing strategies

    • Product safety regulations have increased the demand for pharmacovigilance capacity and expertise. 
    • The atmosphere of drug safety outsourcing is changing to include more complex activities like signal analysis, risk assessment and management, and risk analysis planning.
    • Many pharmaceutical and biotechnology companies are reconsidering their drug safety and patient safety outsourcing strategies.
    • The need for outsourcing varies greatly between companies and is influenced by a variety of variables, such as the size of the company, the extent of its drug safety and patient safety resources, and the company’s existing permits or development collaborations.
    • Because emerging and small biotech firms typically lack drug safety departments, all safety services are outsourced.
    • Mid-sized companies typically have the resources and expertise to meet the global drug safety environment’s demands. However, they necessitate assistance in meeting the fluctuating resource requirements caused by a changing product pipeline. 
    • They are also geographically limited and frequently require additional assistance in unrepresented countries.
    • Large corporations have extensive departments with global facilities and databases; they frequently outsource responsibilities to cut costs. Choosing a vendor necessitates some research and planning.

    Companies should take the following preliminary steps:

    • Establish clear relationship goals and objectives. This includes defining the tasks to be contracted for and weighing the available expertise against the level and number of resources required.

    Outsourcing can be a positive experience if the sponsor and vendor communicate openly and promptly address issues. Such circumstances necessitate extreme flexibility on the part of both parties.

    • Conduct thorough research. Companies should check the references of the provider to gain insight into actual past performance. A track record of regulatory compliance and low nonconformity rates usually indicates the presence of a strong quality management system.

    Examine the business models available for the requested service. Key factors influencing model selection include intricacies and variations, the amount of work involved, and the length of the project.

    Outsourcing Model Types

    • Model-based on resources: A team is staffed to meet the maximum projected volume of a program. This is a less expensive option suitable for programs with relatively stable and predictable workloads.
    • Activity-based model: When the resourcing strategy is projected based on accurate forecasting, this model provides flexibility while also containing costs. It allows for resources to be partially allocated to support additional programs or clients.
    • Blended/transformational model: This is tailored to the company’s specific needs and provides a cost-effective team to support a baseline workload as well as services on a per-unit basis to support periods of high volume.

    Making your relationship work

    Sponsor-outsourcing partner relationships are built on well-defined contractual agreements that are managed within a configuration that matches the scope of work. To achieve efficient and effective collaboration, the following steps must be taken:

    Roles and responsibilities should be defined, establish communication pathways and escalation procedures, create a governance structure, and develop contingency plans for both parties at the start of the alliance.

    The board should hold regular meetings to assess the ongoing relationship and operations. forming an oversight committee composed of executives from both stakeholders in addition to their respective project teams.

    Making investments in face-to-face management sessions to ensure that processes remain aligned, issues are resolved, contract changes are managed, and upgrades are identified is key to achieving organizational success.

     

    Although such actions have an impact on the project budget, they are beneficial in the long run. Resources can be optimized for the greatest possible cost efficiencies with a joint commitment, shared values, high trust, suitable leadership, allied core strengths, and positive company outlooks. The extent and quality of collaboration will determine success.

                                                                Sollers is a terrific place to learn about cutting-edge technology.

    Sollers College is an ideal place to begin a career in PV. Sollers provides PV courses that are both future-relevant and career-defining. 

    Sollers can assist ysou in finding student-friendly financing sources that will benefit you long-term.

  • Drug safety case processing: key issues and strategies to prevent them

    Drug safety case processing: key issues and strategies to prevent them

    Case processing is one of the most crucial aspects of drug safety. It provides data for the analysis of side effects, enabling us to identify newly emerging safety concerns and regularly assess the balance between the risks and benefits of using a pharmacological treatment.

    Safety data processing must be exact and of a high standard from a medical and scientific perspective to give accurate analysis and prompt corrective action, which in turn serves to safeguard the health of the patients and make it possible for the safe use of the drug.

    Why is it so important to ensure the highest degree of case processing quality?

    Case processing, a crucial pharmacovigilance activity, enables the transmission of substantial volumes of safety data across numerous stakeholders, such as patients, physicians, and responsible authorities. Processing a case involves the following steps:

    Case report presentation

    • Prioritization of case reports: duplicate check validation
    • Transmission of a medical evaluation to partners: quality assurance closure for data entry for archiving.
    • When processing cases, it is crucial to ensure the quality of the data.
    • Effective data analysis, scientific evaluation, and decision-making are dependent on the proper handling of case processing tasks, which in turn enables effective public health protection.
    • Observing regulations: To effectively protect the health of patients, safety data must be properly analyzed and used for benefit/risk evaluation and signal detection activities.

    Case processing common mistakes:

    Numerous quality problems are encountered by pharmacovigilance staff members who handle case processing activities. The most typical problem is:

    1. Insufficient reporting

    Contradictory data and coding errors signify an incomplete or inconsistent medical assessment.

    2. Incomplete report mistake 

    The most efficient way to deal with the issue of incomplete data is through routine training. 

    The quality assurance AE/SAE report is also included.

    3. Incorrect coding

    • The most important role of medical coding is to standardize and group disparate phrases into a standard parent category, which is necessary for efficient safety data analysis.
    • Medical coding is crucial for preventing spelling errors, inaccurate abbreviations, or non-standardized terms.
    • Coding mistakes can be avoided with a suitable and transparent source of data. Pharmacovigilance experts, however, occasionally get acronyms and information that are incorrect or unclear.
    • Congestion, of which the type (pulmonary, nasal, hepatic, sinus, etc.) is unclear,
    • Uncertainty about the sort of pain
    • Myocardial infarction (MI) or mitral incompetence (MI) are the two terms that are not entirely clear.
    • It is recommended to speak with the reporter personally to get clarification in such circumstances. The use of lower-level terminology might be permissible if the clarifications weren’t thorough.
    • If the clarifications are not exhaustive, lower-level terminology (LLT) should be used. The “MedDRA Points to Consider” page is also beneficial to review because it has a wealth of examples organized by type of coding issue.

    Narrative

    When crucial details from the case narrative are missing from the structured fields, it is a common type of error for the narrative to be incorrect.

    All information in the narrative must be accurately documented in the pertinent structured fields for pharmacovigilance professionals to promptly examine the cases and enable reliable data retrieval.

    How to Process a Quality Case

    Case processing is an essential task that forms the basis of pharmacovigilance decision-making. It enables the pharmacovigilance team to accurately analyze the safety data and take remedial actions promptly, ensuring that the drug benefits the patients in the best way possible.

    There are many strategies that can help to raise the standard of case processing, including:

    • Employees in clinical development, sales, medical information, legal, and quality control may require additional training.
    • Safety data collection forms that are easy to read and well-designed.
    • Random samples of patients are periodically examined.
    • All data entered into the database is subjected to quality control by a second individual.
    • Regular checking of a sample of instances taken randomly from the database. This can either be a thorough check or a check of the essential fields you’ve chosen.
    • Checking for deviations in KPIs and CAPAs.

                                                      Get the right chance to succeed in society and change things.

     A career in drug safety and pharmacovigilance affords you the chance to make a difference in people’s lives because of the recent increase in demand for pharmaceutical and drug safety specialists.

    Accredited courses in drug safety and pharmacovigilance are available at Sollers College.

  • Digitalization opens new opportunities for pharmacovigilance

    Digitalization opens new opportunities for pharmacovigilance

    Due to continuously expanding market and regulatory constraints, industries have been forced to re-evaluate their safety operations and how they affect operating costs, productivity, quality, audit, and compliance.

    Pharmacovigilance must be integrated into a pharmaceutical company’s daily operations for it to be effective. Pharma businesses revolutionize the entire PV process by leveraging technology. Automation is the initial stage in the transition of PV.

    Document Intelligence

    • Pharmacovigilance activities access a huge amount of varied, dynamic, dispersed, structured, or unstructured data, which presents hurdles in terms of its interpretation due to its complexity, content, and scale.
    • Traditional methods are frequently insufficient for processing the volume of data that is so huge and complex since no actions can be taken on the gathered data without a structured generated document.
    •   Artificial intelligence technology with smart documents and reporting capabilities could be a potential answer to all of this. Such solutions can assist PV professionals in creating templates and streamlining the material so that, when necessary, the necessary data can be fetched in only a few seconds.
    •  It helps to produce data-driven documents because it can process several data sources at once. These systems require fewer people to pull data each day because they have the functionality to interact directly with data sources. It is easier to evaluate the data as and when needed by creating templates that are appropriate to the data and needs.
    •  Conventional data sources have been used as the main data sources for gathering patient safety information on pharmaceuticals and clinical trial outputs. However, none of these by themselves can be used to establish the full safety profile of a product.
    •  Entering the world of big data and concrete proof is therefore vital. By incorporating numerous social media platforms, claims data, electronic health records, wearable platforms, and more, it has greatly increased the number of data sources.
    • Although these new data sources offer helpful information for recognizing safety signals, it takes a lot of effort to process the vast amount of data they produce.
    •  According to the FDA, only the highest quality data should be evaluated and reported. PV professionals may develop reports that are specific to a certain market niche because of the smart document flexibility of AI platforms.
    • Based on conditional logic built right into the document design, they can choose to display or conceal the data. As a result, it takes less effort and money to provide customized and segmented reports.
    • Therefore, the digital revolution brought about increased computer skills that sparked the attention of regulatory agencies, pharmaceutical companies, and researchers in using big data for monitoring medication safety and smart capabilities for creating papers and reports.

    Document Digitization in Pharmacovigilance

    • Document digitization is the first benefit of automation in the PV industry. According to statistics provided by the WHO, drug side effects are the fifth most common cause of mortality. Therefore, pharmacovigilance is essential because modern patients eagerly anticipate learning more about the safety of drugs and treatments.
    •  Companies are required to consider the information on AE from numerous data sources, including chatbots, public forums, social media, and other channels, following the new legal standards.
    • The number of data streams has significantly increased because of this need, which has inevitably resulted in a rise in the amount of data being transmitted.
    • The range of adverse event data and the requirement for analysis have led to a complicated PV process. Separating genuine crisis cases from alerts takes a lot of time amidst the data flow.
    • Pharmaceutical companies must meet regulatory requirements for the integration and management of enormous amounts of data that are used for the evaluation and processing of drug safety information, in addition to the pressure brought on by the market’s production of data.
    • For stakeholders in the pharmaceutical industry to meet these standards, document automation systems must undergo significant modifications.
    •   The document automation system not only speeds up the documentation process but also enables PV specialists to create visually appealing documents that incorporate all the data logic directly into the template.
    •  Adverse events spiral out of control because of the slowdown in signal detection. Document automation is the only way for organizations to efficiently handle such a massive collection of data.

    Automation for Analyzing Adverse Outcomes

    • Adverse event processing is the main objective when it comes to automating PV operations. Pharmaceutical industries spend a significant amount of time, money, resources, and effort to carry out this repetitious procedure properly.
    • The case management procedure in PV is already largely automated. When compared to manual submission of forms, this has increased the quality of submissions. Additionally, electronic submissions happen on their own and don’t affect the schedules for regulatory reporting. Therefore, the impact of AI applications in PV on the effectiveness and efficiency of the work is also anticipated.
    •  The degree of automation in case processing depends on a variety of factors, including the volume of cases, the number of phases in the case processing workflow, and more. This renders some of the manual processes unnecessary.
    •  AI can be used to make the case intake process even simpler. This can make use of both machine learning (ML) and natural language processing (NLP) ideas.  

    Cloud-Based Pharmacovigilance Solutions

    • By keeping a sizable amount of data in the cloud, numerous sectors have profited. The pharmaceutical sector has experienced a boom because of the necessity to maximize data intake, store it, and then analyze it.
    • An expanding number of data sources are now adding to our understanding of the advantages and risks of pharmaceutical goods.
    •  Big data applications for pharmacovigilance have become relevant with the rise of cloud technology. Pharmaceutical businesses will need technologies that are effective to handle the enormous number and diverse data sources surrounding adverse drug reactions to make educated decisions in PV.
    • To provide regulators and those in possession of marketing authorizations with knowledge and valuable information, big data output must be integrated and unified. At the patient or public health level, it can aid in the prevention of severe ADRs.
    • With the help of this large amount of data, the owners of marketing authorizations can defend the market position of their medications.
    • Pharmacovigilance software suppliers are anticipating being able to offer extremely customized and durable solutions that guarantee data security. Users may easily employ signal detection and data analysis approaches as more and more pharmacovigilance data is moved to the cloud to be evaluated.
    • Additionally, the ability to always access the most recent version of pharmacovigilance software without the need for in-house installation will contribute to its wider acceptance.

    Results and Discussion

    • Due to document automation, artificial intelligence, and cloud technologies, pharmacovigilance tasks have already undergone a major revolution.
    • Each new generation of instruments will also improve intelligence and adaptability, expanding the scope of applications to creatively tackle fresh pharmaceutical challenges.
    • The regulatory bodies and the pharmacovigilance firms are aware of the potential for PV with these technologies.
    • Some pharmacovigilance procedures, such as case entry, case processing, and reporting activities, are automated using modern technology.
    • Individual case safety reports (ICSR) can be less time and money-consuming for businesses, freeing up resources for proactive risk assessment, identification, and mitigation.
    •   By implementing technologies like document automation, AI, and cloud-based solutions, pharmaceutical companies can advance toward end-to-end automation across the PV spectrum.

    Students at Sollers College receive education about the regulatory roles that pharmacovigilance plays and how those roles are operationalized.

    Students are equipped with the fundamental knowledge and practical skills needed to meet the demands of the expanding healthcare industry.

     By gaining knowledge of the necessary abilities, you can build a fulfilling profession. Your learning is aided by an all-encompassing program that is in line with Soller’s College. 

     No prior experience? No worries! Participate right away.

×